Bortezomib

硼替佐米

Report date: 2026/04/06 20:01:48
NMEFirst In Class

Base Information

Drug NameBortezomib
Drug Alias Name保特佐米Bortezomibum硼替佐咪硼替左米Velcade +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProteasome inhibitors
TargetsProteasome
Therapy Area/IndicationsRejection of renal transplantationLiver DysfunctionSolid tumours +[94] 
Global Approved IndicationsMultiple MyelomaLymphoma, Mantle-Cell
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryUnited States
Original Approved Date2003/05/13
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMillennium Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityJohnson & Johnson Innovative MedicineAmneal Pharmaceuticals Inc +[8] 
Inactive CompaniesDana-Farber Cancer InstituteGeorgetown UniversitySpectrum Health Corp +[37] 
Active IndicationsProstatic Neoplasms, Castration-ResistantCentral Nervous System NeoplasmsBreast Neoplasms +[8] 
Inactive IndicationsRejection of renal transplantationLiver DysfunctionSolid tumours +[86] 

Other Information

ATC CodeL01XG01
Related LinksWikipediaDrugBankKEGG